| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caab78aa5b332d52d85e0c3b7e348137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f58fa2bd28ba8e77fa637407fc0b71c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f32606f584c5395437a2182bc587a5a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_225e0f0a33179365f4b045cf927dd6c0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 |
| filingDate |
2007-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f5c625876fda890e20dae7eee6a8ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea8a6cc83c513c74c2a156058d368bab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e016e118e3a716a53372d4fbbf25b909
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e647f84445a1dd11f487bbe9b2bddba9 |
| publicationDate |
2009-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2018178-A2 |
| titleOfInvention |
Administration of agonist-antagonist in opioid-dependent patients |
| abstract |
A method for reducing psychological opioid dependence includes selecting a patient addicted to an opioid and administering to the patient an opioid agonist-antagonist for at least 14 days, thereby reducing craving for the opioid in the patient. An opioid agonist-antagonist is administered in a patient needing an average adherence to a treatment protocol of at least 95 percent. A non-injectable formulation containing an agonist-antagonist also is disclosed. |
| priorityDate |
2006-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |